Thoreson N, Park JA, Grasso C, et al. - Researchers sought to determine the epidemiologic features linked with acne development in transgender individuals receiving masculinizing hormone therapy via a cohort study of 988 transgender patients who started masculinizing hormone therapy and followed up for at least 1 year. Findings revealed an overall acne prevalence of 31.1% and a 2-year incidence proportion of 25.1%. Findings revealed a significant correlation of younger age at initiation with acne development for individuals receiving masculinizing hormone therapy. They reported a median of 22.4 years among those who developed acne vs 24.7 years among those who did not. The most likely to develop acne after MHT initiation were patients aged 18 to 21 years.